Clinical utility of the new ASAS criteria for spondyloarthritis and the disease activity score

Current Rheumatology Reports

Volumn 13, Issue 5, 2011, Pages 395-401

  Castillo Gallego, Concepción ^a   Aydin, Sibel Z ^b   Marzo Ortega, Helena ^b,c  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

Ankylosing spondylitis; ASAS classification criteria; ASDAS; Axial spondyloarthritis; BASDAI; Bone marrow edema; Dactylitis; Enthesitis; Peripheral arthritis; Sacroiliitis; Spondyloarthritis

Indexed keywords

BIOLOGICAL MARKER;

ANKYLOSING SPONDYLITIS; ANKYLOSIS SPONDYLITIS DISEASE ACTIVITY SCORE; ARTICLE; ASSESSMENTS IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY; CLINICAL RESEARCH; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; EARLY DIAGNOSIS; HUMAN; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; SCORING SYSTEM; SENSITIVITY ANALYSIS; SPONDYLOARTHROPATHY; STANDARDIZATION;

ACTIVITIES OF DAILY LIVING; DISABILITY EVALUATION; HEALTH STATUS; HUMANS; SEVERITY OF ILLNESS INDEX; SOCIETIES, SCIENTIFIC; SPONDYLARTHRITIS;

EID: 80755128376     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0194-6     Document Type: Article

References (41)

1. van Der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984, 27(4):361-8. (Pubitemid 14134775)
2. Dougados M. Diagnostic features of ankylosing spondylitis. Br J Rheumatol. 1995, 34(4):301-3.
3. Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W, et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol. 1988, 15(7):1109-14.
4. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis. 2006, 65(4):423-32.
5. Dougados M, Dijkmans B, Khan M, Maksymowych W, van Der Linden S, Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis. 2002;61 SUPPL. 3:iii40-50. (Pubitemid 35397344)
6. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev. 2005;2:CD004800.
7. Dougados M, vam der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 1995, 38(5):618-27.
8. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999, 42(11):2325-9. (Pubitemid 30333412)
9. Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol. 2006, 33(4):722-31.
10. Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis. 2006, 65(9):1147-53. (Pubitemid 44277387)
11. Chen J, Liu C. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev. 2004;3:CD004524.
12. Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev. 2006;4:CD004524.
13. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003, 48(6):1667-75. (Pubitemid 36682375)
14. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002, 359(9313):1187-93. (Pubitemid 34304258)
15. Davis Jr JC, Van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003, 48(11):3230-6. (Pubitemid 37409337)
16. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebocontrolled trial (ASSERT). Arthritis Rheum. 2005, 52(2):582-91. (Pubitemid 40216323)
17. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006, 54(7):2136-46. (Pubitemid 44051069)
18. Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebocontrolled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008, 58(7):1981-91. (Pubitemid 351988090)
19. Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, et al. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imagingdetermined early sacroiliitis. Arthritis Rheum. 2009, 60(4):946-54.
20. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009, 60(3):717-27.
21. Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009, 68(6):770-6.
22. •• Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68(6):777-83. In this study, the ASAS criteria for axial SpA were validated in a cohort of 649 patients with chronic back pain.
23. Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral spondyloarthritis. Curr Opin Rheumatol 22(4):375-80.
24. • Rudwaleit M, Jurik AG, Hermann KG, Landewe R, van der Heijde D, Baraliakos X, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMER-ACT MRI group. Ann Rheum Dis 2009, 68(10):1520-7. This report describes a consensus statement by the ASAS/OMERACT MRI expert working group on the definition of positive magentic resonance signal representing active sacroiliitis in SpA. This definition was meant to provide guidance on the interpretation of MRI to be applied in the imaging arm of the new ASAS criteria for axial SpA.
25. •• Bennett AN, McGonagle D, O'Connor P, Hensor EM, Sivera F, Coates LC, et al. Severity of baseline magnetic resonance imagingevident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 2008, 58(11):3413-8. The results of this study show that in patients with early IBP a combination of severe sacroiliitis and HLA-B27 positivity has a high specificity for the development of AS compared with mild or no sacroiliitis, regardless of HLA-B27 status, which confers a low likelihood of developing AS.
26. • Marzo-Ortega H, McGonagle D, O'Connor P, Hensor EM, Bennett AN, Green MJ, et al. Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence. Ann Rheum Dis 2009, 68(11):1721-7. This study reported the results of lumbar and SIJ MRI from 54 patients with IBP, and the relationship between sites and extent of inflammation and HLA-B27 status over 12 months. The results show that lumbar spine and SIJ involvement may occur simultaneously in very early SpA and may be differentiated from noninflammatory back pain by the severity of MRI lesions, and that HLA-B27 is associated with the severity of osteitis and its persistence.
27. Aydin S, Bennett A, Emery P, McGonagle D, Marzo-Ortega H. The new ASAS criteria for axial SpA does not predict the development of mNYC AS at 8 years in a cohort of very early IBP patients [abstract]. Arthritis Rheum. 2010;62 SUPPL. 10:553.
28. Weber U, Lambert RG, Pedersen SJ, Hodler J, Ostergaard M, Maksymowych WP Assessment of structural lesions in sacroiliac joints enhances diagnostic utility of magnetic resonance imaging in early spondylarthritis. Arthritis Care Res (Hoboken). 2010, 62(12):1763-71.
29. Weber U, Lambert RG, Ostergaard M, Hodler J, Pedersen SJ, Maksymowych WP The diagnostic utility of magnetic resonance imaging in spondylarthritis: an international multicenter evaluation of one hundred eighty-seven subjects. Arthritis Rheum. 2010, 62(10):3048-58.
30. • Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011, 70(1):25-31. In this study, the ASAS members validated the new ASAS criteria for peripheral SpA in a cohort of 266 patients with a suspicion of SpA, and then in the entire ASAS study population of 975 patients. These new criteria performed well in patients presenting with peripheral arthritis, enthesitis, and/or dactylitis, but further studies are still needed to evaluate their performance in other settings.
31. Bakker C, Boers M, van Der Linden S. Measures to assess ankylosing spondylitis: taxonomy, review and recommendations. J Rheumatol. 1993, 20(10):1724-30. (Pubitemid 24017576)
32. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994, 21(12):2286-91.
33. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009, 68(1):18-24.
34. • van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68(12):1811-8. This study reported the results of the validation process of the four ASDAS sets for AS in comparison with the BASDAI, its individual components, and physician and patient global assessment of disease activity, showing no major differences between the four ASDAS scores. Based on feasibility, the ASAS membership selected the ASDAS version that included back pain, duration of morning stiffness, patient global assessment, peripheral joint complaints, and CRP as the preferred version.
35. van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993, 20(3):579-81. (Pubitemid 23102498)
36. Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011, 70(1):47-53.
37. Pedersen SJ, Sorensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis. 2010, 69(6):1065-71.
38. Aydin SZBA, Emery P, McGonagle D, Marzo-Ortega H. Disease activity assessment by ASDAS doesn't predict sacroiliac inflammation with MRI in axial SpA [abstract]. Arthritis Rheum. 2010;62 SUPPL. 10:524.
39. Nas K, Yildirim K, Cevik R, Karatay S, Erdal A, Baysal O, et al. Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis. Int J Rheum Dis. 2010, 13(3):240-5.
40. Aydin SZ, Can M, Atagunduz P, Direskeneli H. Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis. Clin Exp Rheumatol. 2010, 28(5):752-5.
41. Eder L, Chandran V, Shen H, Cook RJ, Gladman DD. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis 2010 Jul. 13.